- Company
- Sales activities messed up by COVID-19 crisis
- by Chon, Seung-Hyun Feb 26, 2020 06:29am
- Pharmaceutical companies have already been struggling with earnings this year. Concerned about COVID-19 infection, people are reluctant to visit medical institutions, and their business activities for medical staff are virtually suspended. According to UBIST on the 25th, the total outpatient prescription amount last month was ￦1.25 tril
- Company
- Cenobamate, received the grand prize for KNDA
- by Lee, Seok-Jun Feb 26, 2020 06:29am
- SK Biopharmaceuticals announced on the 24th that a new epilepsy drug, Cenobamate (USA Product Name: Xcopri), was selected as the grand prize for Korea New Drug Award (KNDA). This year's 21st KNDA is the only award in the domestic and international pharmaceutical biohealth industry new drug development sector, sponsored by the private secto
- Company
- COVID-19 delays Cancer Deliberation Committee review
- by Eo, Yun-Ho Feb 25, 2020 06:12am
- The 2019 novel coronavirus, COVID-19, is even affecting pharmaceutical reimbursement listing procedure. According to pharmaceutical industry source, the Korean health authority has canceled the Cancer Treatment Deliberation Committee’s meeting initially scheduled on Feb. 26. Pharmaceutical companies that have been waiting for the de
- Company
- Prescription guidance and label change for Xeljanz on UC
- by Nho, Byung Chul Feb 25, 2020 06:11am
- The Korean health authority is predicted to narrow down the use of Pfizer’s treatment for patients with ulcerative colitis, Xeljanz (tofacitinib citrate) soon. Ministry of Food and Drug Safety (MFDS) is expected to conclude its decision on pharmaceutical safety and revising related indication of Xeljanz, as discussed in-depth with Pfizer
- Company
- Fresenius labor union conflict with management intensifies
- by An, Kyung-Jin Feb 25, 2020 06:11am
- The conflict between labor union and the management of Fresenius Medical Care (FMC) has emerged as the union intensified the fight against the management, who has been uncooperative in paying employees over 14 months and inking an agreement. Korea Democratic Pharmaceutical Union’s FMC Chapter has co-convened a press conference with UNI-G
- Company
- Pneumonia vaccine & immune booster sales surged
- by Kim, Jin-Gu Feb 25, 2020 06:11am
- COVID-19 outbreak lasted for one month, and sales of pneumococcal vaccines and immune boosters also increased. According to the industry on the 20th, Pfizer's pneumococcal vaccine, Prevenar 13, Prevena 13 sales soared during COVID-19 outbreak. According to Chong Kun Dang, which is currently in charge of domestic sales of Prevenar, Preve
- Company
- Reimbursed Imfinzi available for stage 3 lung cancer soon
- by Eo, Yun-Ho Feb 24, 2020 06:28am
- The first immunotherapy option for patients with stage 3 lung cancer, Imfinzi, would soon receive healthcare reimbursement. According to pharmaceutical industry, AstraZeneca and National Health Insurance Service (NHIS) have reached an agreement on the pricing of PD-11 inhibitor Imfinzi injection (duvalumab). The reimbursed indication is
- Company
- GSK-Pfizer Consumer Healthcare JV to kick-off on Feb. 24
- by An, Kyung-Jin Feb 21, 2020 06:37am
- Pfizer Pharmaceutical Korea and GlaxoSmithKline Korea (GSK Korea) have finalized the decision on their joint venture in Korea. Two years since the headquarters have signed a merger deal on consumer healthcare divisions, the two companies are finally ready to begin the joint venture. Pharmaceutical industry source reported on Feb. 20, th
- Company
- SCD Pharm confirms Eylea's US partner
- by Lee, Seok-Jun Feb 21, 2020 06:35am
- In-seok Jeon, SCD Pharm’s CEO, said on the 18th that he had selected US and European partners for Eylea’s Biosimilar (SCD411). Only Senju Pharmaceutical in Japan contracted SCD411. According to CEO Jeon’s remarks, additional export announcements (disclosures, etc.) are imminent. SCD411 is about to launch its global phase III study in th
- Company
- Long-waited reimbursed Ibrance+Faslodex in arm’s reach
- by Eo, Yun-Ho Feb 20, 2020 06:42am
- After two long years, Pfizer is finally in proximity to win reimbursement on Ibrance plus Faslodex combination therapy. Pharmaceutical industry source reported, Drug Reimbursement Evaluation Committee (DREC), under Health Insurance Review and Assessment Service (HIRA), has cleared the combination therapy consisting of Pfizer’s CDK4/6 in
